文献速递胸部肿瘤

amivantamab同步放疗在EGFR或MET变异晚期NSCLC中的安全性与疗效

Safety and efficacy of concurrent radiation therapy with amivantamab in patients with advanced EGFR- or MET-altered non-small cell lung cancer.
PubMed 文献 · Eur J Cancer · 2026-06-13

结果显示同步放疗耐受性良好,未发生≥3级不良事件,姑息放疗症状缓解率87%,寡进展病灶局部控制率80%。

要点

  • 同步姑息放疗与amivantamab耐受性良好,未报告≥3级不良事件
  • 姑息照射症状缓解率87%,寡进展病灶局部控制率80%
  • 放疗后继续amivantamab者中位PFS 4.5个月,中位OS 6个月77%、12个月50%

核心结论

  • 同步姑息放疗与amivantamab在晚期EGFR或MET变异NSCLC中可行且耐受性良好。

主要发现

  • 姑息照射症状缓解率87%,寡进展病灶局部控制率80%。
  • 放疗相关不良事件包括13例1级急性、6例2级急性和3例1级晚期事件,无≥3级事件。
  • 6个月和12个月OS率分别为77%和50%。
  • 放疗后继续amivantamab的11例患者中位PFS 4.5个月、TTD 4.8个月、TTNT 5.5个月。

临床怎么用

  • 对于amivantamab治疗中的晚期EGFR或MET变异NSCLC患者,可考虑同步姑息放疗,需关注不良事件但预期耐受性良好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Amivantamab is increasingly used in EGFR-altered advanced non-small cell lung cancer (NSCLC), but data on the safety and efficacy of concurrent radiation therapy (RT) remain scarce. This study assessed the safety and efficacy of this approach. METHODS: Patients with advanced EGFR- or MET-altered NSCLC who received RT within 3 weeks after amivantamab were retrospectively analyzed. RT-related adverse events (AEs), best clinical and radiological responses, local control (LC), post-RT progression-free survival (PFS), overall survival (OS), time to treatment discontinuation (TTD), and time to new systemic therapy (TTNT) were assessed. RESULTS: Twenty-one irradiation courses were delivered concurrently with amivantamab in 14 patients. Median age was 63 years; 71% were never-smokers; 86% had received prior systemic therapy. Mutations included EGFR ex19del (64%), L858R (14%), ex20ins (14%), and MET exon 14 skipping (7%). RT indications were oligoprogression (29%) and palliation (71%), targeting the brain (19%), thorax (19%), lumbosacral spine (14%), adrenals (10%), and extremities (10%). Median follow-up was 8.0 months for AEs and 9.5 months for oncologic outcomes. Symptom relief was achieved in 87% of irradiations, and LC was maintained in 80% of cases. RT-related AEs included 13 grade 1 acute, six grade 2 acute, and three grade 1 late events; no grade ≥ 3 AEs were reported. The 6- and 12-month OS rates were 77% and 50%, respectively. Among 11 patients continuing amivantamab after RT, median PFS, TTD, and TTNT were 4.5, 4.8, and 5.5 months, respectively. Symptom relief was achieved in 87% of palliative irradiations, and LC was maintained in 80% of oligoprogressive lesions. CONCLUSIONS: Concurrent palliative RT and amivantamab appears feasible and well tolerated. Further validation is warranted.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lavigne D, Le Péchoux C, Botticella A, et al. Safety and efficacy of concurrent radiation therapy with amivantamab in patients with advanced EGFR- or MET-altered non-small cell lung cancer. Eur J Cancer. 2026. PMID: 42296899. doi:10.1016/j.ejca.2026.116881

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。